Inovio Pharmaceuticals Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.31 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $1.21Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $125.1M Enterprise Value $93.6M Shares Outstanding 103.4M diluted Next Earnings Date30 Oct 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Inovio Pharmaceuticals is transitioning from a clinical-stage R&D biotech to a commercial-stage DNA medicines company, anchored by its lead candidate INO-3107 for Recurrent Respiratory Papillomatosis (RRP). The FDA's acceptance of the BLA with a PDUFA date of October 30, 2026, represents a major near-term catalyst. While regulatory uncertainty exists regarding its eligibility for the accelerated approval pathway, the clinical data demonstrates a robust reduction in surgical interventions for RRP patients. Supported by a disciplined cost-reduction strategy and an April 2026 capital raise extending its cash runway into Q1 2027, Inovio offers a highly asymmetric risk-reward profile ahead of its late-2026 regulatory milestones. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$1.80 Mean target$3.43 High · most bullish analyst$6.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $1.8020% The FDA determines INO-3107 is ineligible for accelerated approval and issues a Complete Response Letter (CRL) or requires a full Phase 3 trial under the traditional approval pathway. This delays commercialization by several years, forcing Inovio to raise highly dilutive capital or restructure operations as its cash runway is depleted by early 2027. Base CaseCentral scenario $4.1650% The FDA approves INO-3107 under the accelerated approval pathway following constructive discussions regarding eligibility, or requires minor post-marketing commitments. Inovio initiates a controlled commercial launch in early 2027 supported by its contract sales organization, while continuing to manage its cash burn and advancing its glioblastoma collaboration with Akeso. Bull CaseUpside scenario $6.0030% The FDA grants accelerated approval to INO-3107 on or before the October 30, 2026 PDUFA date without requiring additional clinical trials. Inovio successfully launches INO-3107 in the US, capturing a significant share of the adult RRP market due to its highly differentiated, non-surgical therapeutic profile. Commercial partnerships or non-dilutive licensing deals are secured for next-generation platforms (DPROT/DMAbs), driving substantial upward valuation. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |